Innovent Biologics, Inc. (HKG:1801)
Hong Kong · Delayed Price · Currency is HKD 94.35
-3.85 (-3.92%)
Sep 10, 2026, 4:08 PM HKT
Innovent Biologics Stock Forecast
Stock Price Forecast
According to 29 analysts polled by S&P Global, Innovent Biologics stock has a consensus rating of "Strong Buy" and an average price target of $128.86. The average 1-year stock price forecast is 36.58% higher than the current stock price, while the lowest is $94.31 (-0.04%) and the highest is $149.94 (+58.92%).
Price Target: $128.86 (+36.58%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Innovent Biologics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 21 | 22 | 22 | 22 | 21 | 20 |
| Buy | 5 | 5 | 6 | 6 | 6 | 7 |
| Hold | 3 | 2 | 2 | 1 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 29 | 29 | 30 | 29 | 28 | 29 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst BOCOM International Holdings Company No rating | BOCOM International Holdings Company | Buy Maintains $118.00 → $129.00 | Buy | Maintains | $118.00 → $129.00 | +36.72% | Sep 3, 2026 |
Unknown Analyst UBS No rating | UBS | Buy Maintains $124.10 → $135.30 | Buy | Maintains | $124.10 → $135.30 | +43.40% | Sep 2, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains $117.00 → $140.00 | Buy | Maintains | $117.00 → $140.00 | +48.38% | Aug 28, 2026 |
Unknown Analyst CSC Financial No rating | CSC Financial | Buy Maintains $147.70 → $148.34 | Buy | Maintains | $147.70 → $148.34 | +57.22% | Aug 28, 2026 |
Unknown Analyst Jefferies No rating | Jefferies | Buy Maintains $125.00 | Buy | Maintains | $125.00 | +32.49% | Aug 27, 2026 |
Financial Forecast
Revenue This Year
18.66B
from 13.04B
Increased by 43.10%
Revenue Next Year
22.98B
from 18.66B
Increased by 23.11%
EPS This Year
1.42
from 0.99
Increased by 43.06%
EPS Next Year
2.16
from 1.42
Increased by 52.52%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.